Interferon Alfacon1 is a Potent Inhibitor of SARS-Corona Virus in Cell-Based Models
Abstract
Preliminary data examining interferon alphacon1 treatment of SARS-CoV (severe acute respiratory syndrome-corona virus)-infected patients suggest this therapy is well tolerated and of therapeutic benefit. We report herein that interferon alfacon1, has potent in vitro antiviral activity against SARS-CoV. In a cytopathic effect protection (CPE) assay, interferon alfacon1 inhibited the generation of CPE in a dose-dependent manner with an IC50 of 0.001 g/ml, a clinically achievable level. Furthermore, interferon alphacon1 also demonstrated significant antiviral activity in yield reduction and plaque reduction assays. The in vitro antiviral activity of interferon alphacon1 against SARS-CoV suggests continued evaluation of interferon alphacon1 as a therapeutic treatment for patients infected with SARS-CoV.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 04, 2005
- Accession Number
- ADA434863
Entities
People
- Chris Hartmann
- Jason Paragas
- John W. Huggins
- Lawrence M. Blatt
- Tim P. Endy
Organizations
- United States Army Medical Research Institute of Infectious Diseases